Use of memantine for elderly patients in the mild stage of Alzheimer's and vascular dementia
Bachyns'ka, N.I.; Rozheliuk, I.F.; Polietaieva, K.M.; Kholin, V.O.
Likars'ka Sprava 7: 80-96
2013
ISSN/ISBN: 1019-5297 PMID: 25509921 Document Number: 17000
To evaluate the efficiency menantine (antagonist of NMDA-type glutamate receptor) for treatment of the mild stage of Alzheimer and vascular dementia, we conducted a comprehensive neurological, experimental psychological, neurophysiological examination of 33 patients. It was found that the treatment course with memantine, 5-10 mg daily during 3 months resulted in reducing the severity of cognitive impairment, improved bioelectric activity of the brain in patients with dementia, and also helped to improve the patients' behavior, which resulted in stress loads on the surrounding people. It is shown that the treatment was well tolerated, and memantine may be recommended as one of the drugs for treatment of cognitive impairment accompanying aging in the mild stage of dementia of different genesis.
Document emailed within 1 workday
